In another study, it was found that anti-PD-1 agents could boost EGFR-mutant tumor growth through interaction with M2-like macrophages.24 This case reminded that administration of ICI monotherapy in this subgroup of patients harboring EGFR-KDD should be performed with caution in future clinical practice. The gene discussed is PDCD1; the disease is neoplasm.